NCT04042402 - Long Term Extension Study in Patients With Primary Hyperoxaluria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2030

Conditions

Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney DiseasesUrologic DiseasesGenetic DiseasePrimary Hyperoxaluria Type 3 (PH3)

Interventions

DRUG

DCR-PHXC

Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection

Trial Locations (23)

3052

Clinical Trial Site, Melbourne

4029

Clinical Research Site, Herston

9019

Clinical Trial Site, Tromsø

10016

Clinical Trial Site, New York

53127

Clinical Trial Site, Bonn

55905

Clinical Trial Site, Rochester

69120

Clinical Trial Site, Heidelberg

69500

Clinical Trial Site, Bron

75019

Clinical Trial Site, Paris

94143

Clinical Research Site, San Francisco

02115

Clinical Trial Site, Boston

L8S 4K1

Clinical Research Site, Hamilton

00165

Clinical Research Site, Roma

830-0011

Clinical Trial Site, Fukuoka

467-8601

Clinical Trial Site, Nagoya

183-8561

Clinical Trial Site, Tokyo

Unknown

Clinical Trial Site, Beirut

Clinical Trial Site, Hampstead

Clinical Trial Site, Birmingham

1105AZ

Clinical Trial Site, Amsterdam

08035

Clinical Research Site, Barcelona

Clinical Trial Site, Barcelona

06560

Clinical Trial Site, Ankara

All Listed Sponsors

lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY